DISCO Pharmaceuticals signs AbbVie cancer deal; Merck halts drug
· 2 sources
European Biotechnology Magazine reports DISCO's AbbVie cancer deal, while Benzinga says Merck ended work on an acquired drug after a safety review.
What happened
European Biotechnology Magazine reports that Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery agreement with AbbVie. The German biotech receives $40 million upfront.
The deal could bring up to $2.5 billion in additional payments, according to the publication. It is DISCO's second major pharma partnership this year, after an agreement with Amgen in January.
Separately, Benzinga reports that Merck has pulled the plug on a drug it acquired, following a safety review. The sources provided do not name the drug or give further details.
Context
Drug discovery partnerships between biotech firms and large pharma companies typically pair upfront payments with larger milestone-based payments that depend on future development progress.
Why it matters
The news touches three large drugmakers, AbbVie, Amgen and Merck, and shows how pipeline decisions and partnerships can shape their oncology and development portfolios.
Stocks in this story
Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.
$209.57Fair range: $144.39 to $325.14The price ($286.01) is 36.5% above that figure.
Chance of a rise in 1 month
53%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $276.54 and $298.09; 9 in 10, between $258.74 and $318.60.
$457.77Fair range: $361.54 to $576.63The price ($443.89) is 3.0% below that figure: close to its fair value.
Chance of a rise in 1 month
52%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $424.34 and $466.80; 9 in 10, between $389.95 and $507.97.
$61.72Fair range: $47.12 to $115.85The price ($137.78) is 123.3% above that figure.
Chance of a rise in 1 month
51%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $130.94 and $145.54; 9 in 10, between $119.23 and $159.83.
Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.
Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer
ATLAS Signals
ATLAS Signals, every week
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy